Advertisement

Molecular Medicine

, Volume 17, Issue 9–10, pp 1084–1094 | Cite as

Progesterone Inhibits the Growth of Human Neuroblastoma: In Vitro and In Vivo Evidence

  • Fahim Atif
  • Iqbal Sayeed
  • Seema Yousuf
  • Tauheed Ishrat
  • Fang Hua
  • Jun Wang
  • Daniel J. Brat
  • Donald G. Stein
Research Article

Abstract

We investigated the antitumorogenic effects of progesterone (P4) in a human neuroblastoma (SK-N-AS) cell line in vitro and in a mouse xenograft model of neuroblastoma. The safety of P4 was tested in rat primary cortical neurons and human foreskin fibroblasts (HFF-1). At high doses, P4 significantly (P < 0.05) decreased SK-N-AS cell viability in vitro, and this effect was not blocked either by 5α-reductase inhibitor, finasteride or the P4 receptor antagonist RU486. Even at very high doses, P4 did not induce any cell death in healthy primary cortical neurons or HFF-1. The bioavailability of P4 24 h after the last injection in the serum of treated animals was significantly (P < 0.05) higher (10–33 µg/mL) than in untreated animals. In nude mice, P4 (50 and 100 mg/kg) inhibited neuroblastoma growth by ∼50% over 8 d of treatment. No drug toxicity was observed in the mice, as measured by body weight and activity. P4 suppressed the expression of vascular endothelial growth factor (VEGF) and matrix metalloproteinases (MMP-9, MMP-2), which are involved in tumor vascular development. High-dose P4 inhibited tumor growth by suppressing cell proliferation and inducing apoptosis, as evidenced by the expression of proliferating cell nuclear antigen and cleaved caspase-3. P4 significantly increased the expression of P4 receptor isoform-A and suppressed phospho-Akt (Ser437) expression. In conclusion, at high doses, P4 effectively inhibits the growth of solid neuroblastoma tumor and has high bioavailability, selective toxicity and a high margin of safety making it a possible candidate for further study as a potential clinical treatment of neuroblastoma.

Notes

Acknowledgments

The authors thank Leslie McCann for invaluable editorial assistance. F Atif thanks Bilal B Hafeez (Department of Human Oncology, University of Wisconsin Madison, WI, USA) for constructive discussions. We thank Brian Leyland-Jones and his laboratory group in the Winship Cancer Center of Emory University for careful review of this manuscript and thoughtful suggestions for improvement. We are also grateful for the consistent support of Emory College and the Laney Graduate School of Arts and Sciences.

References

  1. 1.
    Heck JE, Ritz B, Hung RJ, Hashibe M, Boffetta P. (2009) The epidemiology of neuroblastoma: a review. Paediatr. Perinat. Epidemiol. 23:125–3.CrossRefPubMedGoogle Scholar
  2. 2.
    Atif F, Sayeed I, Ishrat T, Stein DG. (2009) Progesterone with vitamin D affords better neuroprotection against excitotoxicity in cultured cortical neurons than progesterone alone. Mol. Med. 15:328–36.CrossRefPubMedPubMedCentralGoogle Scholar
  3. 3.
    Brinton RD, et al. (2008) Progesterone receptors: form and function in brain. Front Neuroendocrinol 29:313–39.CrossRefPubMedPubMedCentralGoogle Scholar
  4. 4.
    Dressing GE, Lange CA. (2009) Integrated actions of progesterone receptor and cell cycle machinery regulate breast cancer cell proliferation. Steroids. 74:573–6.CrossRefPubMedGoogle Scholar
  5. 5.
    Peck JD, et al. (2002) Steroid hormone levels during pregnancy and incidence of maternal breast cancer. Cancer Epidemiol Biomarkers Prev. 11:361–8.PubMedGoogle Scholar
  6. 6.
    Bu SZ, et al. (1997) Progesterone induces apoptosis and up-regulation of p53 expression in human ovarian carcinoma cell lines. Cancer. 79:1944–50.CrossRefPubMedGoogle Scholar
  7. 7.
    Formby B, Wiley TS. (1999) Bcl-2, survivin and variant CD44 v7–v10 are downregulated and p53 is upregulated in breast cancer cells by progesterone: inhibition of cell growth and induction of apoptosis. Mol. Cell. Biochem. 202:53–61.CrossRefPubMedGoogle Scholar
  8. 8.
    Horita K, et al. (2001) Progesterone induces apoptosis in malignant mesothelioma cells. Anti-cancer Res. 21:3871–4.Google Scholar
  9. 9.
    Medina D, Kittrell FS, Tsimelzon A, Fuqua SA. (2007) Inhibition of mammary tumorigenesis by estrogen and progesterone in genetically engineered mice. Ernst Schering Found. Symp. Proc. (1):109–26.Google Scholar
  10. 10.
    Guzman RC, et al. (1999) Hormonal prevention of breast cancer: mimicking the protective effect of pregnancy. Proc. Natl. Acad. Sci. U. S. A. 96:2520–5.CrossRefPubMedPubMedCentralGoogle Scholar
  11. 11.
    Benakanakere I, et al. (2006) Natural and synthetic progestins accelerate 7,12-dimethylbenz[a]anthracene-initiated mammary tumors and increase angiogenesis in Sprague-Dawley rats. Clin. Cancer Res. 12:4062–71.CrossRefPubMedGoogle Scholar
  12. 12.
    Liang Y, Besch-Williford C, Brekken RA, Hyder SM. (2007) Progestin-dependent progression of human breast tumor xenografts: a novel model for evaluating antitumor therapeutics. Cancer Res. 67:9929–36.CrossRefPubMedGoogle Scholar
  13. 13.
    Benakanakere I, Besch-Williford C, Carroll CE, Hyder SM. (2010) Synthetic progestins differentially promote or prevent 7,12-dimethylbenz(a)anthracene-induced mammary tumors in Sprague-Dawley rats. Cancer Prev. Res. (Phila). 3:1157–67.CrossRefGoogle Scholar
  14. 14.
    Yager JD, Davidson NE. (2006) Estrogen carcinogenesis in breast cancer. N. Engl. J. Med. 354:270–82.CrossRefPubMedGoogle Scholar
  15. 15.
    Seeger H, Mueck AO. (2008) Are the progestins responsible for breast cancer risk during hormone therapy in the postmenopause? Experimental vs. clinical data. J. Steroid Biochem. Mol. Biol. 109:11–5.CrossRefPubMedGoogle Scholar
  16. 16.
    de Lignieres B, et al. (2002) Combined hormone replacement therapy and risk of breast cancer in a French cohort study of 3175 women. Climacteric. 5:332–40.CrossRefPubMedGoogle Scholar
  17. 17.
    Fournier A, Berrino F, Clavel-Chapelon F. (2008) Unequal risks for breast cancer associated with different hormone replacement therapies: results from the E3N cohort study. Breast Cancer Res. Treat. 107:103–11.CrossRefPubMedGoogle Scholar
  18. 18.
    Kramer EA, Seeger H, Kramer B, Wallwiener D, Mueck AO. (2006) The effect of progesterone, testosterone and synthetic progestogens on growth factor- and estradiol-treated human cancerous and benign breast cells. Eur. J. Obstet. Gynecol. Reprod. Biol. 129:77–83.CrossRefPubMedGoogle Scholar
  19. 19.
    Wiebe JP, Lewis MJ, Cialacu V, Pawlak KJ, Zhang G. (2005) The role of progesterone metabolites in breast cancer: potential for new diagnostics and therapeutics. J. Steroid Biochem. Mol Biol 93:201–8.CrossRefPubMedGoogle Scholar
  20. 20.
    Purmonen S, Manninen T, Pennanen P, Ylikomi T. (2008) Progestins regulate genes that can elicit both proliferative and antiproliferative effects in breast cancer cells. Oncol. Rep. 19:1627–34.PubMedGoogle Scholar
  21. 21.
    Van Maerken T, et al. (2009) Antitumor activity of the selective MDM2 antagonist nutlin-3 against chemoresistant neuroblastoma with wild-type p53. J. Natl. Cancer Inst. 101:1562–74.CrossRefPubMedGoogle Scholar
  22. 22.
    Hsu SM, Raine L, Fanger H. (1981) Use of avidin-biotin-peroxidase complex (ABC) in immunoperoxidase techniques: a comparison between ABC and unlabeled antibody (PAP) procedures. J. Histochem. Cytochem. 29:577–80.CrossRefPubMedGoogle Scholar
  23. 23.
    Park JR, Eggert A, Caron H. (2008) Neuroblastoma: biology, prognosis, and treatment. Pediatr. Clin. North Am. 55:97–120, x.CrossRefPubMedGoogle Scholar
  24. 24.
    Goss CW, Hoffman SW, Stein DG. (2003) Behavioral effects and anatomic correlates after brain injury: a progesterone dose-response study. Pharmacol. Biochem. Behav. 76:231–42.CrossRefPubMedGoogle Scholar
  25. 25.
    Ishrat T, Sayeed I, Atif F, Stein DG. (2009) Effects of progesterone administration on infarct volume and functional deficits following permanent focal cerebral ischemia in rats. Brain Res. 1257:94–101.CrossRefPubMedGoogle Scholar
  26. 26.
    Van Landingham JW, et al. (2008) Progesterone and its metabolite allopregnanolone differentially regulate hemostatic proteins after traumatic brain injury. J. Cereb. Blood Flow Metab. 28:1786–94.CrossRefGoogle Scholar
  27. 27.
    Wiehle RD, Christov K, Mehta R. (2007) Antiprogestins suppress the growth of established tumors induced by 7,12-dimethylbenz(a)anthracene: comparison between RU486 and a new 21-substituted-19-nor-progestin. Oncol. Rep. 18:167–74.PubMedGoogle Scholar
  28. 28.
    Paulssen RH, Moe B, Gronaas H, Orbo A. (2008) Gene expression in endometrial cancer cells (Ishikawa) after short time high dose exposure to progesterone. Steroids. 73:116–28.CrossRefPubMedGoogle Scholar
  29. 29.
    Sugiura Y, Shimada H, Seeger RC, Laug WE, De-Clerck YA. (1998) Matrix metalloproteinases-2 and -9 are expressed in human neuroblastoma: contribution of stromal cells to their production and correlation with metastasis. Cancer Res. 58:2209–16.PubMedGoogle Scholar
  30. 30.
    Kim JJ, Chapman-Davis E. (2010) Role of progesterone in endometrial cancer. Semin. Reprod. Med. 28:81–90.CrossRefPubMedPubMedCentralGoogle Scholar
  31. 31.
    Brazil DP, Park J, Hemmings BA. (2002) PKB binding proteins: getting in on the Akt. Cell. 111:293–303.CrossRefPubMedGoogle Scholar
  32. 32.
    Francois F, Grimes ML. (1999) Phosphorylation-dependent Akt cleavage in neural cell in vitro reconstitution of apoptosis. J. Neurochem. 73:1773–6.CrossRefPubMedGoogle Scholar
  33. 33.
    Kastner P, et al. (1990) Two distinct estrogen-regulated promoters generate transcripts encoding the two functionally different human progesterone receptor forms A and B. EMBO J. 9:1603–14.CrossRefPubMedPubMedCentralGoogle Scholar
  34. 34.
    Richer JK, et al. (2002) Differential gene regulation by the two progesterone receptor isoforms in human breast cancer cells. J. Biol. Chem. 277:5209–18.CrossRefPubMedGoogle Scholar
  35. 35.
    Li J, Fang X, Chen X, Chen J. (2008) Selective expression of progesterone receptor in malignant melanoma was inversely correlated with PCNA. J. Huazhong Univ. Sci. Technolog. Med. Sci. 28:216–8.CrossRefPubMedGoogle Scholar
  36. 36.
    Inoue T, et al. (2002) Progesterone production and actions in the human central nervous system and neurogenic tumors. J. Clin. Endocrinol. Metab. 87:5325–31.CrossRefPubMedGoogle Scholar
  37. 37.
    Fjelldal R, Moe BT, Orbo A, Sager G. (2010) MCF-7 cell apoptosis and cell cycle arrest: non-genomic effects of progesterone and mifepristone (RU-486). Anticancer Res. 30:4835–40.PubMedGoogle Scholar
  38. 38.
    Moe BT, Vereide AB, Orbo A, Jaeger R, Sager G. (2009) Levonorgestrel, medroxyprogesterone and progesterone cause a concentration-dependent reduction in endometrial cancer (Ishikawa) cell density, and high concentrations of progesterone and mifepristone act in synergy. Anticancer Res. 29:1047–52.PubMedGoogle Scholar
  39. 39.
    Wang L, et al. (2011) Glucocorticoid receptors take part in the apoptotic process of human lens epithelial cells, but the glucocorticoid receptor antagonist RU486 does not rescue the cells fully. Mol. Biosyst. 7:1926–37.CrossRefPubMedGoogle Scholar
  40. 40.
    Tieszen CR, Goyeneche AA, Brandhagen BN, Ortbahn CT, Telleria CM. (2011) Antiprogestin mifepristone inhibits the growth of cancer cells of reproductive and non-reproductive origin regardless of progesterone receptor expression. BMC Cancer. 11:207.CrossRefPubMedPubMedCentralGoogle Scholar
  41. 41.
    Wagner BL, et al. (1996) 16 alpha-substituted analogs of the antiprogestin RU486 induce a unique conformation in the human progesterone receptor resulting in mixed agonist activity. Proc. Natl. Acad. Sci. U. S. A. 93:8739–44.CrossRefPubMedPubMedCentralGoogle Scholar
  42. 42.
    Meyer ME, et al. (1990) Agonistic and antagonistic activities of RU486 on the functions of the human progesterone receptor. EMBO J. 9:3923–32.CrossRefPubMedPubMedCentralGoogle Scholar
  43. 43.
    Mizutani T, Bhakta A, Kloosterboer HJ, Moudgil VK. (1992) Novel antiprogestins Org 31806 and 31710: interaction with mammalian progesterone receptor and DNA binding of antisteroid receptor complexes. J. Steroid. Biochem. Mol. Biol. 42:695–704.CrossRefPubMedGoogle Scholar
  44. 44.
    Kloosterboer HJ, Deckers GH, Schoonen WG. (1994) Pharmacology of two new very selective antiprogestagens: Org 31710 and Org 31806. Hum. Reprod. 9 Suppl 1:47–52.CrossRefPubMedGoogle Scholar

Copyright information

© The Feinstein Institute for Medical Research 2011
www.feinsteininstitute.org

Authors and Affiliations

  • Fahim Atif
    • 1
  • Iqbal Sayeed
    • 1
  • Seema Yousuf
    • 1
  • Tauheed Ishrat
    • 1
  • Fang Hua
    • 1
  • Jun Wang
    • 1
  • Daniel J. Brat
    • 2
    • 3
  • Donald G. Stein
    • 1
  1. 1.Department of Emergency Medicine, Brain Research LaboratoryEmory UniversityAtlantaUSA
  2. 2.Department of Pathology and Laboratory Medicine, School of MedicineEmory UniversityAtlantaUSA
  3. 3.Winship Cancer InstituteEmory UniversityAtlantaUSA

Personalised recommendations